References
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14):977–86
- Diabetes Control and Complications Trial Research Group. The Absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45(10):1289–98
- Bolli GB. The pharmacokinetic basis of insulin therapy in diabetes mellitus. Diabetes Res Clin Pract 1989; 6(4):3–15S
- Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983; 6(4):374–7
- Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43(Mar):396–402
- Roach P, Varshavsky JA, Gantner K, et al. Insulin antibody formation during treatment with human insulin or insulin lispro does not affect insulin dose requirements. (Abstr) Diabetes 1996; 45(Suppl):261A
- Lougheed WD, Zinman B, Strack TR, et al. Chemical stability of insulin lispro in insulin infusion systems. (Abstr) Diabetes 1996; 45(Suppl):198A
- Zinman B, Chiasson JL, Tildesley H, et al. Insulin lispro in CSII: results of a double-blind, cross-over study. (Abstr) Diabetes 1996; 45(Suppl):28A
- Torlone E, Fanelli C, Rambotti AM, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994; 37:713–20
- Antsiferov M, Woodworth JR, Mayorov A, et al. Lower within patient variability in postprandial glucose excursion with lispro insulin analog compared with regular insulin. (Abstr) Diabetes 1995; 44(Suppl 1):214A
- Torlone E, Pampanelli S, Lalli C, et al. Postprandial glycemic control in IDDM after se LYS, PRO insulin analogue or human regular insulin, alone or mixed with NPH. (Abstr) Diabetes 1995; 44(Suppl 1):71A
- Trautmann M, Brunelle R, Koivisto V, et al. Reduction of postprandial glucose rise by insulin lispro is independent from pre-meal glucose values. (Abstr) Diabetes 1996; 45(Suppl):121A
- Trautmann ME. Effect of the insulin analogue [LYS(B28), PRO(B29)] on blood glucose control. Horm Metab Res 1994; 26:588–90
- Anderson J, Brunelle R, Pfüetzner A, et al. Reduced frequency of hypoglycemia without loss of glycemic control. (Abstr) Diabetes 1996; 45(Suppl):59A
- Anderson JH Jr, Brunelle RL, Vignati L. Insulin lispro compared to regular insulin in a crossover study involving 1037 patients with type I diabetes. (Abstr) Diabetes 1995; 44(Suppl 1):228A
- Bastyr EJ 3d, Kotsanos J, Vignati L, et al. Insulin lispro (LP) reduces hypoglycemia rate in persons with type II diabetes at high risk for hypoglycemia. (Abstr) Diabetes 1996; 45(Suppl)56A
- Bergenstal R, Spencer M, Castle G, et al. Intensive insulin management of type I and type II diabetes: a comparison of [Lys(B28), Pro(B29) human insulin] (LP) and regular human insulin (REG). (Abstr) Diabetes 1994; 43(Suppl 1):157A
- Pfüetzner A, Gudat UW, Trautmann ME. Longterm use of insulin lispro in intensive insulin therapy. (Abstr) Diabetes 1996; 45(Suppl):284A
- Brunelle RL, Symanowski S, Anderson JH Jr, et al. Less nocturnal hypoglycemia with insulin lispro in comparison to human regular. (Abstr) Diabetes 1995; 44(Suppl 1):111A
- Sackey AH, Jefferson IG. Interval between insulin injection and breakfast in diabetes. Arch Dis Child 1974; 71(3):248–50
- Garg AK, Carmain JA, Braddy KC, et al. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type I diabetes. Diabet Med 1996; 13(1):47–52
- Vignati L, Brunelle R. Treatment of 722 patients with type II diabetes with insulin lispro in a 6 month crossover study. (Abstr) Diabetes 44; 1995 (Suppl 1):834A
- Tuominen JA, Karonen SL, Melamies L, et al. Exercise- induced hypoglycaemia in IDDM patients treated with a short- acting insulin analogue. Diabetologia 1995; 38:106–11
- Price Alert 1996 Oct 15:38
- Desmet M, Rutters A, Schmitt H, et al. [Lys(B28), Pro (B29)] human insulin (LysPro). Patients treated with lispro vs human regular insulin: quality of life assessment (QOL). (Abstr) Diabetes 1994; 43(Suppl 1):167A
Selected readings
- Bruce DG, Chisolm DJ, Storlien LH, et al. Physiological importance of deficiency in early prandial insulin secretion in non-insulin- dependent diabetes. Diabetes 1988; 37(Jun):736–44
- Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1993; 326:22–9
- Pampanelli S, Torlone E, Lalli C, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care 1995; 18(11): 1452–9
- Rowe BR, Pizzey M, Barnett AH. A clinical evaluation of the B-D Pen. Pract Diabetes 1992; 9(4):138–9
- Zar J. Biostatistical analysis. Englewood Cliffs, NJ: Prentice Hall, 1984